Rebuttal from Ms Woodford and Dr Senthi

Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II).

BMJ open·2026

Blood dosimetry during volumetric modulated arc therapy for non-small cell lung cancer: A time-resolved model of circulating particles.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2026

Version upgrades in treatment planning Systems affect clinical application of a multi-Centre knowledge-based planning model.

Technical innovations & patient support in radiation oncology·2026

Prophylactic Cranial Irradiation Versus Active MRI Surveillance in Small Cell Lung Cancer: Systematic Review and Meta-Analysis.

Journal of medical imaging and radiation oncology·2026

Stereotactic Ablative Radiotherapy (SABR) one stop service for lung cancer: A pilot study for early-stage Non-Small-Cell Lung Cancer (NSCLC).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026